Asgel Zeynep, Kouakou Manuela R, Koller Dora, Pathak Gita A, Cabrera-Mendoza Brenda, Polimanti Renato
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain.
J Affect Disord. 2024 May 1;352:333-341. doi: 10.1016/j.jad.2024.02.061. Epub 2024 Feb 19.
There is still a limited understanding of the dynamics contributing to the comorbidity of COVID-19 and anxiety outcomes.
To dissect the pleiotropic mechanisms contributing to COVID-19/anxiety comorbidity, we used genome-wide data from UK Biobank (up to 420,531 participants), FinnGen Project (up to 329,077 participants), Million Veteran Program (175,163 participants), and COVID-19 Host Genetics Initiative (up to 122,616 cases and 2,475,240 controls). Specifically, we assessed global and local genetic correlation and genetically inferred effects linking COVID-19 outcomes (infection, hospitalization, and severe respiratory symptoms) to anxiety disorders and symptoms.
We observed a strong genetic correlation of anxiety disorder with COVID-19 positive status (rg = 0.35, p = 2×10) and COVID-19 hospitalization (rg = 0.31, p = 7.2×10). Among anxiety symptoms, "Tense, sore, or aching muscles during worst period of anxiety" was genetically correlated with COVID-19 positive status (rg = 0.33, p = 0.001), while "Frequent trouble falling or staying asleep during worst period of anxiety" was genetically correlated with COVID-19 hospitalization (rg = 0.24, p = 0.004). Through a latent causal variable analysis, we observed that COVID-19 outcomes have statistically significant genetic causality proportion (gcp) on anxiety symptoms (e.g., COVID-19 positive status→"Recent easy annoyance or irritability" │gcp│ = 0.18, p = 6.72×10). Conversely, anxiety disorders appear to have a possible causal effect on COVID-19 (│gcp│ = 0.38, p = 3.17×10). Additionally, we also identified multiple loci with evidence of local genetic correlation between anxiety and COVID-19. These appear to be related to genetic effects shared with lung function, brain morphology, alcohol and tobacco use, and hematologic parameters.
This study provided insights into the pleiotropic mechanisms linking COVID-19 and anxiety outcomes, suggesting differences between dynamics related to anxiety disorders and those related to anxiety symptoms.
目前对于导致新冠病毒病(COVID-19)与焦虑症共病的动态机制仍了解有限。
为剖析导致COVID-19/焦虑症共病的多效性机制,我们使用了来自英国生物银行(多达420,531名参与者)、芬兰基因计划(多达329,077名参与者)、百万退伍军人计划(175,163名参与者)以及COVID-19宿主遗传学倡议(多达122,616例病例和2,475,240名对照)的全基因组数据。具体而言,我们评估了将COVID-19结局(感染、住院和严重呼吸道症状)与焦虑症及症状联系起来的全局和局部遗传相关性以及遗传推断效应。
我们观察到焦虑症与COVID-19阳性状态(rg = 0.35,p = 2×10)以及COVID-19住院(rg = 0.31,p = 7.2×10)之间存在很强的遗传相关性。在焦虑症状中,“焦虑最严重时期肌肉紧张、酸痛或疼痛”与COVID-19阳性状态存在遗传相关性(rg = 0.33,p = 0.001),而“焦虑最严重时期频繁难以入睡或保持睡眠”与COVID-19住院存在遗传相关性(rg = 0.24,p = 0.004)。通过潜在因果变量分析,我们观察到COVID-19结局对焦虑症状具有统计学上显著的遗传因果比例(gcp)(例如,COVID-19阳性状态→“近期容易烦恼或易怒” │gcp│ = 0.18,p = 6.72×10)。相反,焦虑症似乎对COVID-19有潜在因果效应(│gcp│ = 0.38,p = 3.17×10)。此外,我们还鉴定出多个位点,有证据表明焦虑与COVID-19之间存在局部遗传相关性。这些似乎与肺功能、脑形态、烟酒使用及血液学参数共有的遗传效应有关。
本研究深入探讨了将COVID-19与焦虑症结局联系起来的多效性机制,表明与焦虑症相关的动态机制和与焦虑症状相关的动态机制存在差异。